Nearly 6.7 million adults in the U.S. have heart failure, with prevalence expected to rise to 8.5 million by 20301,2. While heart failure is a chronic, progressive disease, advances in technology are ...

St. Jude Medical’s CardioMEMS HF System demonstrates our commitment to delivering high-quality, innovative solutions that reduce health care costs and improve outcomes for patients ST. PAUL, Minn.-- ...

Mark Carlson, St. Jude Medical’s chief medical officer, explains how the CardioMEMS HF System might evolve and shares his vision for the future of epidemic disease care. Heart failure patients used to ...

ST. PAUL, Minn. -- St. Jude Medical, Inc., a global medical device company, today announced a new data analysis from the CHAMPION clinical trial that evaluated outcomes in a subgroup of patients with ...

May 28 (Reuters) - St. Jude Medical Inc said on Wednesday it plans to exercise its option to buy the shares of CardioMEMS it does not already own for $375 million following news the Food and Drug ...

The CardioMEMS HF System is proven to significantly reduce heart failure hospitalizations and improve quality of life in NYHA class III HF patients St. Jude Medical now intends to exercise its ...

(RTTNews) - Abbott (ABT) said that the U.S. Food and Drug Administration has approved an expanded indication for the company's CardioMEMS HF System to support the care of more people living with heart ...

The US Food and Drug Administration (FDA) has expanded the indication for Abbott's CardioMEMS heart failure (HF) system, making an additional 1.2 million patients in the United States eligible for the ...

Abbott Laboratories ABT recently gained FDA approval of an expanded indication for its CardioMEMS HF System to support the care of heart failure patients. The CardioMEMS HF System has been found to ...

Add Yahoo as a preferred source to see more of our stories on Google. Abbott's CardioMEMS cardiac sensor will now be available to patients with chronic heart failure through the NHS. Image credit: ...

St. Jude Medical's CardioMEMS acquisition brought to the Minnesota device a breakthrough heart monitoring device meant to serve as an early alert system for chronic heart failure patients. The FDA ...

WASHINGTON (Reuters) - A Food and Drug Administration review of CardioMEMS' device for treating heart failure found it has met its main safety and effectiveness goals, based on trial results. But the ...